


BPH “watchful waiting” changes to Thermobalancing therapy

By POSTED BY KATHY COLACE and COMMUNITY CONTRIBUTOR NOV 12, 2018 | 5:28 AM



<https://www.latimes.com/dp-ugc-article-bph-watchful-waiting-changes-to-thermobalan-2018-11-12-story.html>

Benign prostatic hyperplasia (BPH) is a non-cancerous condition of the prostate, which affects 50% of men in their 60th, and most of them will suffer lower urinary tract symptoms (LUTS). By the age of 80, LUTS due to BPH affects 80% men.

BPH doesn't increase the risk of prostate cancer and it isn't considered a health problem unless it causes symptoms. Therefore, prostate enlargement or BPH is usually a non-life-threatening condition.

Many years ago, "watchful waiting" for men with BPH was introduced, in which time is allowed to pass before risky medical or surgical intervention is used.

Innovative Thermobalancing therapy and Dr Allen's device been working very well for BPH during the last decade, which is the main reason to change "watchful waiting" to Thermobalancing therapy.

1. Standard treatment options for BPH have serious side effects

Medications used for BPH, alpha-blockers, tamsulosin, and 5-alpha-reductase inhibitors, finasteride and dutasteride, Avodart and Proscar, have serious side effects such as weakness, retrograde ejaculation, impotence and diabetes.

In the past 2 months have been published articles about Post-finasteride Syndrome (PFS) exploring that the medical community has an obligation not to turn a blind eye on this debilitating condition.

These recent articles are: "The Post-finasteride Syndrome: Clinical Manifestation of Drug-Induced Epigenetics Due to Endocrine Disruption" and "Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?" The discussions explore serious sexual dysfunction that can occur after use of these drugs.

Furthermore, medications do not stop the progress of chronic prostate enlargement.

Problems related to standard treatments support debates on question: is early BPH treatment

worthwhile? These talks are usually associated with medical and surgical intervention.

Some urologists believe that as a result of delayed surgery after prolonged medical treatment, patients show larger prostates, older age, and comorbidities. However, evidence supporting early treatment is not enough, and the criteria for discriminating patients who mostly can benefit from immediate treatment remain poorly defined.

2. Safety and effectiveness of Thermobalancing therapy with Dr Allen's Device for Prostate Treatment

This non-invasive therapy and device received a US patent, No. US 9,408,744 B2, as "Therapeutic device and method".

Thermobalancing therapy is based on a new understanding of The Origin of Diseases, which explains that all chronic internal diseases start at the vascular level. This knowledge helps to tackle the cause of prostate enlargement with the use of Thermobalancing therapy, and therefore it is able to reduce the size of enlarged prostate.

A clinical study on Thermobalancing therapy in men with BPH confirmed that Dr Allen's Device as monotherapy stops and even reverses prostate enlargement. Accordingly, to decrease of enlarged prostate in size, the urinary symptoms in 124 men reduced dramatically

without adverse events.

It should be mentioned that Dr Allen's Device is a Class I Medical Device, which does not require the involvement of a Notified Body at any country. So, everyone can use it at home without worrying, as this treatment option causes no side effects.

3. Focus on changing "watchful waiting" to Thermobalancing therapy

Physicians is the first instance that are accessed by men with LUTS associated with BPH, so for them it is important to clearly define what to do.

Thermobalancing therapy should be administered to men in the first place, when the enlarge prostate is diagnosed. Why? Because, Dr Allen's Device that enables Thermobalancing therapy is effective and safe.

Another reason for prescribing innovative device is the cost-effectiveness of this therapy. The investigation of annual costs of BPH medical treatment found that outpatient costs are about US\$1.800 and the overall annual spending for BPH is about US\$5.800. With the price less than US\$200, Dr Allen's device compares preferably to standard treatment options.

It should be noted that for over a decade Fine Treatment delivers the innovative health-giving device to anyone's home worldwide, from Oxford, UK.

An article: "In the guidelines for physicians and urologists "watchful waiting" for benign prostatic

hyperplasia (BPH) should be replaced with Thermobalancing therapy that treats prostate effectively, cost-effectively and safely" is published in the scientific medical journal. According to this article, treatment with Dr Allen's device for prostate treatment should be carried out at an early stage of this disorder.

Thus, the use of Thermobalancing therapy with Dr Allen's therapeutic device in "watchful waiting" will definitely help men to avoid risky treatments and, consequently, to improve their quality of life.